Cymarin - Misplaced Pages

This is an old revision of this page, as edited by The chemistds (talk | contribs) at 22:46, 6 September 2011 (Added CSID, (std)InChI, and (std)InChIkey). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 22:46, 6 September 2011 by The chemistds (talk | contribs) (Added CSID, (std)InChI, and (std)InChIkey)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound

Cymarin
Clinical data

Other names	Cymarine; K-Strophanthin-α; NSC 7522; Strophantin K; WV 90043a; k-Strophanthin-α
ATC code	C01AC03 (WHO)
Identifiers
IUPAC name (3S,5S,8R,10S,13R,14S,17R)-5,14-dihydroxy-3-((2R,4S,5S,6R)-5-hydroxy-4-methoxy-6-methyltetrahydro-2H-pyran-2-yloxy)-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1H-cyclopentaphenanthrene-10-carbaldehyde
CAS Number	508-77-0
PubChem CID	10504
UNII	UK3LS8435E
ChEMBL	ChEMBL1651908
CompTox Dashboard (EPA)	DTXSID20871714
ECHA InfoCard	100.007.353
Chemical and physical data
Formula	C₃₀H₄₄O₉
Molar mass	548.665 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C\1OC/C(=C/1)2CC6(O)2(C)CC46CC5(O)C(O3O((O)(OC)C3)C)CC45C=O
InChI InChI=1S/C30H44O9/c1-17-26(33)23(36-3)13-25(38-17)39-19-4-9-28(16-31)21-5-8-27(2)20(18-12-24(32)37-15-18)7-11-30(27,35)22(21)6-10-29(28,34)14-19/h12,16-17,19-23,25-26,33-35H,4-11,13-15H2,1-3H3/t17-,19+,20-,21+,22-,23+,25+,26-,27-,28+,29+,30+/m1/s1 Key:XQCGNURMLWFQJR-ZNDDOCHDSA-N
(what is this?) (verify)

Cymarin (or cymarine) is a cardiac glycoside. Apocynum cannabinum used as a source of fiber by Native Americans and Apocynum venetum (Chinese: 羅布麻) used as a herbal tea in China both contain cymarin. Cymarin is a cardiogenic toxin that causes cardiac arrhythmia in humans. Cymarin is used in modern medicine in formulated pharmaceutical preparations used to treat a variety of tumors.

References

Edible and Medicinal plants of the West, Gregory L. Tilford, ISBN 0-87842-359-1
The Merck Index, 12th Edition, 2830

Cardiac glycosides (C01A)

Bufadienolides

Bufo	Arenobufagin Bufotalin Cinobufagin Marinobufagin
Scilla	Proscillaridin Scilliroside
Kalanchoe	Daigremontianin

Cardenolides

Digitalis	Acetyldigitoxin Acetyldigoxin Digitoxin Digoxin Lanatoside C Deslanoside Metildigoxin Gitoformate
Strophanthus	Ouabain (g-Strophanthin) k-Strophanthin Cymarin
Thevetia	Peruvoside

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: